Skip to main content
Precision Medicine For AML Patients - LLS's Beat AML® Master Clinical Trial
Precision Medicine For AML Patients - LLS's Beat AML® Master Clinical Trial

Beat AML® is transforming treatment for people with acute myeloid leukemia

Doctors diagnose over 20,000 Americans with acute myeloid leukemia (AML) each year, making it one of the most common types of leukemia — and one of the most aggressive.

In 2016, The Leukemia & Lymphoma Society (LLS) launched the Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced technology to examine the genetic make-up of each patient’s cancer and then matches patients to the most promising targeted treatment.

So far, Beat AML has:

  • Improved survival for AML patients enrolled in a Beat AML study (compared to standard chemotherapy)
  • Facilitated precision medicine treatment for over 400 AML patients in a Beat AML sub-study
  • Sequenced AML genomes for over 1,400 patients
  • Offered clinical studies to treat 15 unique types of AML


Coloring Outside the Lines

Coloring Outside the Lines, a new documentary from award-winning independent filmmakers and LLS, follows four cancer patients given months or less to live and chronicles their experience in the Beat AML trial.

Watch: Donna Kelley’s experience with Beat AML

Watch: Darlene Chroniger’s experience with Beat AML

What makes the Beat AML Master Clinical Trial groundbreaking?

LLS brought together a range of blood cancer experts to collaborate like never before to disrupt the status quo in AML treatment

The master clinical trial protocol allows different patients, depending on the genetic features of their AML, to enroll in Beat AML sub-studies using different treatment approaches

Advanced technology provides genomic analysis to match patients to precision treatment within seven days

Precision medicine approach moves people away from one-size-fits-all chemotherapy

Beat AML Master Clinical Trial

Beat AML Leadership

John C. Byrd, MD

University of Cincinnati College of Medicine

Brian Druker, MD

The Knight Cancer Institute at Oregon Health & Science University

Ross L. Levine, MD

Memorial Sloan Kettering Cancer Center in New York City

Ashley Yocum, PhD

Beat AML Master Protocol Lead, The Leukemia & Lymphoma Society

AML Facts

There are more than 10 types of AML and other rare mutations

Each type of AML responds to different therapies

Only 1 in 3 adults with AML survives five years, this drops to 1 in 6 for adults diagnosed at 60 and older

More than 11,000 Americans die of AML each year

Learn more about the LLS Beat AML Master Trial

How LLS is leading the way in AML research

  • The Beat AML Master Clinical trial continues to grow by:
    • Testing precision medicine for adults with AML
    • Exploring ways to reduce side effects and improve patients’ quality of life
    • Making clinical trials more patient friendly by using new technology to monitor vital signs, symptoms, and side effects of treatment with fewer trips to the doctor
  • The Pediatric Acute Leukemia (PedAL) Master Clinical Trial matches children with AML to precision medicine therapies
  • Over 25% of the research LLS funds is aimed at finding cures and improving quality of life for AML patients—that’s $60 million!
  • The LLS Therapy Acceleration Program has over 20 active investments in AML therapies currently in development